DESCRIPTION

This international, multidisciplinary journal covers all aspects of neuromuscular disorders in childhood and adult life (including the muscular dystrophies, spinal muscular atrophies, hereditary neuropathies, congenital myopathies, myasthenias, myotonic syndromes, metabolic myopathies and inflammatory myopathies).

The Editors welcome original articles from all areas of the field:
- Clinical aspects, such as new clinical entities, case studies of interest, treatment, management and rehabilitation (including biomechanics, orthotic design and surgery).
- Basic scientific studies of relevance to the clinical syndromes, including advances in the fields of molecular biology and genetics.
- Studies of animal models relevant to the human diseases.

The journal is aimed at a wide range of clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.

In addition to original research papers, the journal also publishes reviews and mini-reviews, preliminary short communications and book reviews, and has editorial, correspondence and news sections. Reports on congresses and workshops, taking the form of a digested or very comprehensive commentary, pointing out some of the particular highlights in relation to the contributors and giving some detail of the area covered, important contributions and a list of participants, are also welcome.

The journal is published monthly and aims at rapid publication of high quality papers of scientific merit as well as general interest to a wide readership. There is also a fast track for rapid publication of new material of outstanding scientific merit and importance.

*Neuromuscular Disorders* is the official journal of the *World Muscle Society* an international, multidisciplinary, scientific society, dedicated to the advancement and dissemination of knowledge in the field of neuromuscular disorders.

AUDIENCE

Clinicians, pathologists, associated paramedical professionals and clinical and basic scientists with an interest in the study of neuromuscular disorders.
IMPACT FACTOR

2022: 2.800 © Clarivate Analytics Journal Citation Reports 2023

ABSTRACTING AND INDEXING

Current Contents - Life Sciences
PubMed/Medline
Neuroscience Citation Index
Reference Update
Research Alert
Science Citation Index
Web of Science
Scopus

EDITORIAL BOARD

Editor-in-Chief
Anders Oldfors, University of Gothenburg, Göteborg, Sweden

Editorial Assistant
Jane Miller, University College London Institute of Child Health, London, United Kingdom

Founding Editor-in-Chief
Victor Dubowitz, University College London Institute of Child Health, London, United Kingdom

Gene Table Editor
Gisele Bonne, National Institute of Health and Medical Research, Paris, France
Human genetic, Pathophysiology, laminopathy, nuclear envelope, muscular dystrophy

Executive Associate Editors
Ronald D. Cohn, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
(Fast Track, Reviews)
Vincenzo Nigro, University of Campania Luigi Vanvitelli, Caserta, Italy
Haluk Topaloglu, Yeditepe University School of Medicine, Istanbul, Turkey
Pediatrics and Neurology
Bjarne Udd, Vaasa Central Hospital Neurological and Internal Medicine Unit E5, Vasa, Finland

Associate Editors
Gillian Butler-Browne, Sorbonne University Pierre and Marie Curie Campus, Paris, France
(Animal Models) , myology, skeletal muscle, myoblasts, ageing, regeneration, neuromuscular disease
Giovanni Meola, University of Milan, Milano, Italy
Neuromuscular Disorders, Myotonic Disorders, Myotonic Dystrophies, Skeletal Muscle
Channelopathies, Periodic Paralysis
Luciano Merlini, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Ichizo Nishino, National Center of Neurology and Psychiatry, Kodaira, Japan
Myology, Myositis, Myopathy
Benedikt Schoser, LMU Munich, München, Germany
Neurology
Duygu Selcen, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States of America
G. Shelton, University of California San Diego, La Jolla, California, United States of America
Muscle, Nerve, Pathology, Comparative
Werner Stenzel, Charite University Hospital Berlin, Berlin, Germany
myology, myopathology, neuropathology, neurology
Volker Straub, Newcastle University, Newcastle Upon Tyne, United Kingdom
Beril Talim, Hacettepe University, Ankara, Turkey
Giorgio Tasca, John Walton Muscular Dystrophy Research Centre, Newcastle Upon Tyne, United Kingdom
Neurology, Neuromuscular disorders, muscular dystrophy, myopathy, muscle imaging
Peter Van den Bergh, University Hospital Saint-Luc The Neuromuscular Reference Center, Bruxelles, Belgium
Nicol Voermans, Radboud University, Nijmegen, Netherlands
genotype - phenotype coupling, trial readiness, optimal symptomatic treatment and trial fitness, and clinical trials

**Editorial Board**

**Helge Amthor**, Institute of Myology, Paris, France

**Corrado Angelini**, University of Padua, Padova, Italy

Metabolic Disorders, Muscular Dystrophy

**Zohar Argov**, Hebrew University of Jerusalem School of Medicine, Jerusalem, Israel

neuromuscular disorders

**David Beeson**, John Radcliffe Hospital, Oxford, United Kingdom

**Enrico Bertini**, Bambino Gesù Pediatric Hospital, Roma, Italy

Neuropathology, Genetics, Neuromuscular Disease

**Johann Böhm**, Institut of Genetics and Molecular and Cellular Biology, Ilkirch Graffenstaden, France

Genetics, physiopathology, congenital myopathies

**Arthur Burghes**, The Ohio State University, Columbus, Ohio, United States of America

**Patrick F. Chinnery**, Newcastle University Centre for In Vivo Imaging, Newcastle upon Tyne, United Kingdom

**Maxwell Damian**, Addenbrookes Hospital, Neurosciences Critical Care Unit, Cambridge, United Kingdom

**Annamaria De Luca**, University of Bari, Department of Pharmacy and Pharmacology, Bari, Italy

**Feza Deymeer**, Istanbul, Turkey

Neuromuscular diseases

**Salvatore DiMauro**, Columbia University, New York, New York, United States of America

**Dickson**, Royal Holloway University of London, Department of Biological Sciences, Egham, United Kingdom

**Sandra Donkervoort**, National Institutes of Health, Bethesda, Maryland, United States of America

Pediatric neuromuscular disease

**James Dowling**, The Hospital for Sick Children, Toronto, Ontario, Canada

**Alessandra Ferlini**, University of Ferrara, Ferrara, Italy

**Ana Ferreiro**, University Paris Cité, Paris, France

Neuromuscular neurology, muscle translational research, congenital myopathies

**Richard S. Finkel**, Nemours Children's Clinic, Orlando, Florida, United States of America

**Kevin Flanigan**, Nationwide Children's Hospital, Columbus, Ohio, United States of America

**Julaine Florence**, Washington University in St Louis School of Medicine, Saint Louis, Missouri, United States of America

**A. Reghan A.R. Foley**, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Neurogenetics Branch, Bethesda, Maryland, United States of America

**Heidi Fuller**, Keele University, Staffordshire, United Kingdom

Neuromuscular disorders, Spinal muscular atrophy, SMA, CMT1A, LMNA, congenital muscular dystrophy, proteomics, bioinformatics, antibodies

**Hans Goebel**, Charite University Hospital Berlin, Berlin, Germany

**Nathalie Goemans**, KU Leuven University Hospitals Neuromuscular Reference Center, Leuven, Belgium

**Yukiko K. Hayashi**, National Center of Neurology and Psychiatry National Institute of Neuroscience, Department of Molecular Pharmacology, Tokyo, Japan

**Rita R. Horvath**, University of Cambridge, Department of Clinical Neurosciences John Van Geest Cambridge Centre for Brain Repair, Cambridge, United Kingdom

neurology, neuromuscular diseases, mitochondrial diseases, Charcot-Marie-Tooth disease

**Susan Iannaccone**, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America

Pediatric neuromuscular disease

**Jean-Claude Kaplan**, Hospital Cochin, Paris, France

**Parvaneh Karimzadeh**, Shahed Beheshti University of Medical Sciences, Tehran, Iran

Pediatric Neurology, Neurometabolic, Metaboic Myopathy, Neurodevelopment, Neuroimaging

**Martin Lammens**, University Hospital Antwerp, Edegem, Belgium

Neuropathology, Muscle pathology, Nemaline myopathy, Developmental neuropathology

**Maria Isabel Leite**, John Radcliffe Hospital, Oxford, United Kingdom

**Wen-Chen Liang**, Kaohsiung Medical University, Kaohsiung, Taiwan

Neuromuscular disease, Pediatric Neurology, Muscle pathology, Clinical trial

**Silvere S. van der Maarel**, Leiden University Medical Centre Center for Human and Clinical Genetics, Leiden, The Netherlands

Neuromuscular Disorders, Genetics and Epigenetics of chromatin disorders, FSHD, single cell analysis, genomics

**Lorenzo Maggi**, Foundation IRCCS Carlo Besta Neurological Institute, Milano, Italy

Laminopathies, congenital myasthenic syndromes, myasthenia gravis, spinal muscular atrophy, myofibrillar myopathies, distal myopathies, myositis, channelopathies

**Edoardo Malfatti**, University Paris-Est Créteil, Faculty of Medicine, Creteil, France

Neuromuscular Disorders
Emma E. Matthews E., UCL Queen Square Institute of Neurology, Department of Neuromuscular Diseases, Faculty of Brain Sciences, London, United Kingdom
Craig McDonald, UC Davis Medical Center, Sacramento, California, United States of America
Payam Mohassel, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Neuromuscular disease

Federica Montagnese, LMU Munich, München, Germany
Neuromuscular Diseases, Myopathies, Myasthenia, Myotonic Syndromes, FSHD, Pompe, Myositis
Francesco Muntoni, Dubowitz Neuromuscular Centre, London, United Kingdom
Kanneboyina Nagaraju, Children’s National Hospital, Washington, District of Columbia, United States of America
Carmen Navarro, Hospital do Meixoeiro, Vigo, Spain
Merrilee Needham, MOSMAN PARK, Western Australia, Australia
Neuromuscular; Neurogenetics, Neuroimmunology
Montse Olivé, Bellvitge University Hospital Neurology Service, Barcelona, Spain
Richard Orrell, UCL Queen Square Institute of Neurology, London, United Kingdom

Neurology, neuromuscular disorders, ALS, neuropathy, myoopathy, amyotrophic lateral sclerosis, motor neuron diseases

Sergey Paushkin, Spinal Muscular Atrophy Foundation, New York, New York, United States of America
Luisa Politano, University of Campania Luigi Vanvitelli, Caserta, Italy
Jo J. Poulton, University of Oxford, Nuffield, Department of Women’s and Reproductive Health, Oxford, United Kingdom

Mitochondria, mitochondrial DNA, mtDNA, mitophagy
Ros Quinlivan, National Hospital for Neurology and Neurosurgery, London, United Kingdom
Gina Ravenscroft, Perth, Western Australia, Australia
Mary Reilly, National Hospital for Neurology and Neurosurgery, London, United Kingdom
Valerie Ricotti, University College London, London, United Kingdom
Deborah Ridout, University College London Institute of Child Health, London, United Kingdom

Statistics, biostatistics, research design, paediatrics
Carmelo Rodolico Rodolico, Messina, Italy
neuromuscular junction disorders, myasthenia gravis, inflammatory myopathies
Norma Beatriz Romero, INSERM Paris Île-de-France Center East Delegation, Paris, France

Myology; Muscle Histopathology; Congenital Myopathies
Urs Rüegg, University of Geneva, Genève, Switzerland
Pharmacology, Skeletal muscle, calcium signalling
Marco Savarese, Folkhälso Research Center, HELSINKI, Finland

genetics, transcriptomics, molecular diagnosis, distal myopathy, LGMD
Ulrike Schara, University of Duisburg-Essen, Duisburg, Germany
Laurent Servais, Oxford, United Kingdom

Outcome measures, newborn screening, clinical trials
Caroline Sewry, Dubowitz Neuromuscular Centre, London, United Kingdom

muscle pathology
Michael Shy, The University of Iowa, Iowa City, Iowa, United States of America
Charlotte Sumner, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Neuroscience; Genetics: Neuromuscular disease
Shin’ichi Takeda, National Center of Neurology and Psychiatry National Institute of Neuroscience, Kodaira, Japan

Jantima Tanboon, Mahidol University, Faculty of Medicine Siriraj Hospital, Department of Pathology, Bangkok, Thailand

Neuropathology, Muscle pathology, Inflammatory myopathy, Hereditary myopathy
Eduardo Tizzano, Barcelona, Spain
Ana Töpf, Newcastle upon Tyne, United Kingdom
Antonio Toscano, University of Messina, Messina, Italy

Mar Tulinius, Sahlgrenska University Hospital Queen Silvia’s Hospital for Children and Young People, Göteborg, Sweden

Chris Turner, National Hospital for Neurology and Neurosurgery, London, United Kingdom
Mariz Vainzof, University of Sao Paulo, SAO PAULO, Brazil

Myogenesis, muscle regeneration, genetic variability, myopathies, muscular dystrophies
Marianne de Visser, Amsterdam UMC Location AMC, Amsterdam, The Netherlands

Neuromuscular disorders, palliative care
John Vissing, University of Copenhagen, København, Denmark
Karim Wahbi, Hospital Cochin, Paris, France
Zhaoxia Wang, Peking University First Hospital, Beijing, China

neuromuscular disorders, mitochondrial diseases
Conrad Weihl, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States of America
Nanna Witting, København Ø, Denmark
Myopathy phenotypes and genetics, myasthenia gravis
GUIDE FOR AUTHORS

Types of Paper

Research Articles
Regular original research articles should be sent to the main Editorial Office. There is no restriction on length though most articles are between 2500 and 6000 words long. Please contact the Editorial Office if you wish to discuss. The Editor-in-Chief or an appropriate Executive Associate Editor will handle the submission. (For more information on Executive Associate Editors please see Editor’s Commentary. Neuromuscular Disorders, Volume 26, Issue 1, January 2016, Pages 1-4.)

Animal Models for Neuromuscular Diseases
Gillian Butler-Browne will be allocated research articles submitted under this section. There is no restriction on length though most articles are between 2500 and 6000 words long. Please contact the Editorial Office if you would like to discuss.

Veterinary Myology
Diane Shelton will be pleased to receive research articles covering clinical or investigative aspects of spontaneously occurring myopathies, neuropathies or disorders of neuromuscular transmission in domestic animals. There is no restriction on length though most articles are between 2500 and 6000 words long. Please contact the Editorial Office if you would like to discuss.

In addition to submitting regular original research articles, letters and meeting reports, we invite readers to submit interesting articles to the special sections listed below. All items should be submitted online in the usual way to the main Editorial Office in London, with the relevant article type selected from the drop-down menu. If you wish to discuss anything with section editors prior to submission please refer to the journal homepage online or the inside front cover of the printed journal for up-to-date contact information of each section editor.

Reviews
Review papers should cover recent, important developments related to diagnosis, pathogenesis or therapy of a neuromuscular disorder. They can be either in-depth and comprehensive, or short, mini-reviews. Please include an abstract and key words. Reviews will be directed to Anders Oldfors who will co-ordinate peer review. There is no upper limit on the length though most articles do not exceed 6000 words. Please contact the Editorial Office if you would like to discuss.

Case Reports
Case reports should be of interest to the multidisciplinary readership of Neuromuscular Disorders and have a neuromuscular component. Topics such as sensory neuropathies and ataxias are of limited interest to our readership. Case reports should not exceed 2000 words and may include up to three tables or figures and a maximum of 25 references. They should take the form of Title, Abstract (up to 150 words), Introduction, Case Report, Discussion, Acknowledgements and References. Please note that key clinical information must be included in the abstract. Case reports will be directed to Beril Talim who will co-ordinate the editorial process.

Picture of the Month
Please send an interesting picture, clinical, pathological or imaging, of clinical challenge or interest. This should be accompanied by a brief case presentation and discussion, highlighting the special features of the picture, in no more than 300 words and up to three references (no abstract is required). The picture should be the main part of the presentation and be of adequate size and good quality.

Clinical Casebook
Contributions will be welcome for this section for cases that show a conflict of interpretation between the clinical and the investigative aspects of a case, with a view to raising questions, promoting thinking and discussion and potentially opening new channels of research to advance our knowledge.

Historical Reports
We welcome articles of historical interest. These can be sent to the Editorial Office in the first instance and will be redirected to the Historical Section Editor.

ENMC Workshop Reports
These submissions will be treated as a report on a workshop, with the convenor(s) listed as corresponding author(s). They will not be subjected to peer review and, after approval by the Editor, will be published in the next available issue of the journal. The workshop report should be concise and follow the agenda of the workshop - it has the nature of a workshop report, not of a review article (setting the stage for future developments).

The length of a report will vary depending on the number of topics discussed. Workshop reports need to be succinct, focusing on the new information. The references should be confined to those directly relevant to the workshop. Up to three tables, figures or photos may be included. No abstract is required.

1. The basic format of the ENMC-based workshop reports will be the same as in the past with a TITLE reflecting the number of the ENMC workshop, the number if appropriate of the topic workshop and the location and date.

2. A full list of all PARTICIPANTS will be included at the end of the report, with their city and country. This list will also include any ENMC representative as appropriate with [ENMC] after their name.

3. Full ACKNOWLEDGEMENT will be given to ENMC and all its sponsoring organisations at the end of the report using the exact wording as requested by ENMC as one of the conditions in their original letter of acceptance of the workshop.

4. In principle, only the workshop organizers will be the author(s) of the workshop report.

The organizers are to make sure that the tasks of all workshop participants regarding the preparation of the meeting report will have been discussed prior to closing the workshop.

All workshop participants will be included in the “ENMC XXXX Workshop Study Group*”, so that they can be found in PubMed as co-authors of the workshop report. The workshop participants/report authors will be mentioned in an Appendix under the asterisk. The maximum number of authors for a workshop report (including the “ENMC study group”) will be five – so a maximum of four (organizer) names can be used for the workshop report.

The list of authors will be included on the first page of the report, under the title, with a similar format to original papers in the journal. A full but preferably brief address can be included for each author, and the corresponding author for proofs and reprints should also be indicated.

5. As in the past, these reports will not be subjected to any peer review and it will be assumed that the content has the approval of all participants of the workshop. Once approved by the editor, the report will be given priority publication in the next available issue of the journal.

6. Keywords can be provided for reference.

Contact details for submission
Authors may send queries concerning the submission process, manuscript status or journal procedures to the Editorial Office (jane.miller@ucl.ac.uk).

BEFORE YOU BEGIN
Ethics in publishing
Please see our information on Ethics in publishing.

Description of variants (mutations)
Authors are required to follow the recommendations of the HGVS to describe sequence variants (see http://www.HGVS.org/mutnomen/ for a summary of the current recommendations).

Submission of data to a genetic database
In keeping with the recommendations of the Human Variome Project (Cotton RG et al 207. Nat Genet 39:433 http://www.nature.com/ng/journal/v39/n4/full/ng2024.html) authors submitting a manuscript to Neuromuscular Disorders are required to submit all variants and phenotype descriptions to a public database prior to acceptance. Authors must declare the status of database submission in their covering letter upon submission to the journal. In addition, authors should indicate in
their manuscript the database(s) to which they have submitted the variants, and provide the URL. For further information and links to gene variant databases either use GeneSymbol.lovd.nl (e.g. TP53.lovd.nl) or visit the following website: http://www.hgvs.org/content/databases-tools.

**Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

**Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double anonymized) or the manuscript file (if single anonymized). If there are no interests to declare then please state this: 'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal’s official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Declaration of generative AI in scientific writing**

The below guidance only refers to the writing process, and not to the use of AI tools to analyse and draw insights from data as part of the research process.

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier's AI policy for authors.

Authors should disclose in their manuscript the use of AI and AI-assisted technologies in the writing process by following the instructions below. A statement will appear in the published work. Please note that authors are ultimately responsible and accountable for the contents of the work.

**Disclosure instructions**

Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled ‘Declaration of Generative AI and AI-assisted technologies in the writing process’.

**Statement:** During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references etc. If there is nothing to disclose, there is no need to add a statement.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where
the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-
holder. To verify compliance, your article may be checked by Crossref Similarity Check and other
originality or duplicate checking software.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy.
Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple,
redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,
and promotes equal opportunities. Content should make no assumptions about the beliefs or
commitments of any reader; contain nothing which might imply that one individual is superior to
another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition; and use inclusive language throughout. Authors should ensure that writing is free from bias,
stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek
gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible
to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer
to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health
condition unless they are relevant and valid. When coding terminology is used, we recommend
to avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". We
suggest using alternatives that are more appropriate and (self-) explanatory such as "primary",
"secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to help
identify appropriate language but are by no means exhaustive or definitive.

Reporting sex- and gender-based analyses
Reporting guidance
For research involving or pertaining to humans, animals or eukaryotic cells, investigators should
integrate sex and gender-based analyses (SGBA) into their research design according to funder/
sponsor requirements and best practices within a field. Authors should address the sex and/or gender
dimensions of their research in their article. In cases where they cannot, they should discuss this
as a limitation to their research's generalizability. Importantly, authors should explicitly state what
definitions of sex and/or gender they are applying to enhance the precision, rigor and reproducibility
of their research and to avoid ambiguity or conflation of terms and the constructs to which they
refer (see Definitions section below). Authors can refer to the Sex and Gender Equity in Research
(SAGER) guidelines and the SAGER guidelines checklist. These offer systematic approaches to the use
and editorial review of sex and gender information in study design, data analysis, outcome reporting
and research interpretation - however, please note there is no single, universally agreed-upon set of
guidelines for defining sex and gender.

Definitions
Sex generally refers to a set of biological attributes that are associated with physical and physiological
features (e.g., chromosomal genotype, hormonal levels, internal and external anatomy). A binary sex
categorization (male/female) is usually designated at birth ("sex assigned at birth"), most often based
solely on the visible external anatomy of a newborn. Gender generally refers to socially constructed
roles, behaviors, and identities of women, men and gender-diverse people that occur in a historical
and cultural context and may vary across societies and over time. Gender influences how people view
themselves and each other, how they behave and interact and how power is distributed in society. Sex
and gender are often incorrectly portrayed as binary (female/male or woman/man) and unchanging
whereas these constructs actually exist along a spectrum and include additional sex categorizations
and gender identities such as people who are intersex/have differences of sex development (DSD) or
identify as non-binary. Moreover, the terms "sex" and "gender" can be ambiguous—thus it is important
for authors to define the manner in which they are used. In addition to this definition guidance and
the SAGER guidelines, the resources on this page offer further insight around sex and gender in
research studies.

Contributors
Each author is required to declare their individual contribution to the article: all authors must have
materially participated in the research and/or article preparation, so roles for all authors should be
described. The statement that all authors have approved the final article should be true and included
in the disclosure.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.
Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal uses the Elsevier Article Transfer Service to find the best home for your manuscript. This means that if an editor feels your manuscript is more suitable for an alternative journal, you might be asked to consider transferring the manuscript to such a journal. The recommendation might be provided by a Journal Editor, a dedicated Scientific Managing Editor, a tool assisted recommendation, or a combination. If you agree, your manuscript will be transferred, though you will have the opportunity to make changes to the manuscript before the submission is complete. Please note that your manuscript will be independently reviewed by the new journal. More information.

Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement, it is recommended to state this.

Open access
Please visit our Open Access page for more information about open access publishing in this journal.

Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the Language Editing service available from Elsevier's Language Services.
Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
Please submit your article via Editorial Manager

PREPARATION

Queries
For questions about the editorial process (including the status of manuscripts under review) or for technical support on submissions, please visit our Support Center.

Peer review
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. More information on types of peer review.

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure

Text
Papers should be organized in the following format: Abstract (which must consist of a single paragraph only and no sub-headings), Introduction, Materials (or Patients) and Methods, Results and Discussion. Other descriptive headings and sub-headings may be used if appropriate. Every effort should be made to avoid jargon and non-standard abbreviations. Contents of the study should be presented as clearly and as concisely as possible.

Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, …), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.
Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstract
A concise and factual abstract (up to 200 words for full length articles and 150 words for case reports) is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, references should be avoided, but if essential, then cite the author(s) and year(s). It should comprise one complete paragraph with no subheadings. Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Any ambiguous symbols (e.g. the letter 'O' vs the numeral '0', the letter 'I' vs the numeral '1') should be identified. Unnecessary abbreviations should be avoided.

At his discretion the Editor-in-Chief will convert any such abbreviations into their unabbreviated form in order to maintain the flow and sense of the text.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzzzz]; and the United States Institutes of Peace [grant number aaaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points

• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

**Please do not:**
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

**Please note:** Figures and tables must be presented in portrait format, or, if landscape, must fit across a portrait page and still be legible for the print journal. Please ensure that any lettering is large enough to read on the journal's print pages.

**Colour artwork**
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. For colour reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please note that since the journal Neuromuscular Disorders has a significant print circulation, it is essential that any figures requiring colour should be published in colour in print. The cost for colour reproduction is 200 Euros for the first figure and 100 Euros for each additional figure. For further information on the preparation of electronic artwork, please see https://www.elsevier.com/artworkinstructions.

**Figure captions**
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

If the figure has been published previously a credit line should be included.

**Tables**
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

Tables should be submitted online as a separate file and should bear a short descriptive title. If a table must exceed one typewritten page, duplicate all headings on the second sheet. Every column in the table should have an abbreviated heading. Define all abbreviations and indicate the units of measurements for all values. Explain all empty spaces or dashes. Indicate footnotes to the table with the superscript symbols cited in order as you read the table horizontally. Unless tables are unavoidably wide, please present them in portrait format with adequate left and right-hand margins to ensure they do not default to landscape presentation at the typesetters.

**References**

**Citation in text**
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

**Reference links**
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, Crossref and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.
A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the name of the preprint server, as part of the reference. The preprint DOI should also be provided.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given. List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

All co-authors in a reference should be included where there are up to six. If there are more than six, include the names of the first six plus 'et al'. Type references double spaced. References cited only in tables or figure legends should be numbered in accordance with a sequence established by the first mention in the text of a particular table or figure. The authors are responsible for the accuracy and completeness of the references.

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings, which may also include software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.
Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Research Elements
This journal enables you to publish research objects related to your original research – such as data, methods, protocols, software and hardware – as an additional paper in a Research Elements journal.

Research Elements is a suite of peer-reviewed, open access journals which make your research objects findable, accessible and reusable. Articles place research objects into context by providing detailed descriptions of objects and their application, and linking to the associated original research articles. Research Elements articles can be prepared by you, or by one of your collaborators.

During submission, you will be alerted to the opportunity to prepare and submit a manuscript to one of the Research Elements journals.

More information can be found on the Research Elements page.

Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please also complete the submission checklist and upload this with the files for your submission. For further details of any item please consult this Guide for Authors.

Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Phone numbers
All necessary files have been uploaded, and contain:
• Keywords
• Highlights
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction
• Each figure or table must be loaded up to the website and labelled individually, and not embedded in the main text.

For any further information please visit our Customer Support site at https://service.elsevier.com.
AFTER ACCEPTANCE

Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or a link will be provided in the e-mail so that authors can download the files themselves. To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com